A patient-centered discovery platform that identifies and validates ultra-specific individual cancer targets using cellular atlases, computational biology, and antibody engineering.

A preclinical bispecific T-cell engager targeting an undisclosed tumor-surface protein expressed across multiple hematological malignancies and solid tumors.

A discovery-stage single-target and logic-gated therapeutic program for hepatocellular cancer built from Cartography's target-discovery platforms.

A patient-centered discovery platform that nominates and validates complementary cancer target pairs for greater cell selectivity and logic-gated therapeutic strategies.

A Phase 1 bispecific T-cell engager engineered for anti-tumor activity across MSS and MSI-low colorectal cancer.

A discovery-stage logic-gated therapeutic program for pancreatic cancer based on tumor-selective target combinations identified through Cartography's platform.